Article thumbnail

Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients

By Flavia RR Mangone, Fernando Walder, Simone Maistro, Fátima S Pasini, Carlos N Lehn, Marcos B Carvalho, M Mitzi Brentani, Igor Snitcovsky and Miriam HH Federico
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2885344
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2001). A new mathematical model for relative quantification in realtime RT-PCR.
  2. (2001). Aikou T: Preserved Smad4 expression in the transforming growth factor beta signaling pathway is a favorable prognostic factor in patients with advanced gastric cancer. Clin Cancer Res
  3. (2002). Aikou T: Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res
  4. (2002). Akhurst RJ, Balmain A: Metastasis is driven by sequential elevation
  5. (2002). Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res
  6. (2003). C: SMAD7 is a prognostic marker in patients with colorectal cancer.
  7. (2010). Chiang KN: Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness.
  8. (2007). CS: TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol
  9. (1999). DB: Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.
  10. (2005). Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol
  11. (2004). development of chemically induced skin tumors in mice. Vet Pathol
  12. (2006). Dysregulated TGF-beta1-induced Smad signalling occurs as a result of defects in multiple components of the TGF-beta signalling pathway in human head and neck carcinoma cell lines.
  13. (2007). Expression and significance of
  14. (2003). Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res
  15. (2008). HG: Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res
  16. (2004). human gastric carcinomas. Ann Oncol
  17. (2003). Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci
  18. (2006). Kähäri VM: Activation of Smad signaling enhances collagenase -3 expression and invasion of head and neck carcinoma cells. Oncogene
  19. (1998). Kawabata M: Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun
  20. (2006). Kuwano H: Lack of activated Smad2 in transforming growth factor-beta signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinoma. J Surg Oncol
  21. (2004). Kuwano H: Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGFbeta superfamily, in esophageal squamous cell carcinoma. Anticancer Res
  22. (2001). MH: Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck
  23. (2010). Miyazono K: Cellular context-dependent "colors" of transforming growth factor-b signaling. Cancer Sci
  24. (1997). Miyazono K: Smad6 inhibits signalling by the TGF-beta superfamily. Nature
  25. (2009). Moustakas A: Regulating the stability of TGFbeta receptors and Smads. Cell Res
  26. (2009). Moustakas A: Regulating the stability of TGFβ receptors and Smads. Cell Research
  27. (2001). Muñoz-Antonia T: Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin Cancer Res
  28. (2008). Pavasant P: TGFbeta1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway. Biochem Biophys Res Commun
  29. (2007). Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2, N0 tumours. Anticancer Res
  30. (2006). Regulation of Smad activities.
  31. (1996). Saji S: Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology
  32. (1999). Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun
  33. (2007). Su GH: Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett
  34. (1996). T: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res
  35. (1999). The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene
  36. (2000). Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res
  37. (2008). Violette SM: Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res
  38. (2006). Wong DT: Loss of p12 cd2-ap1 expression in human oral squamous cell carcinoma with disrupted trasnforming growth factor β-Smad signaling patway. Neoplasia
  39. (2009). XF: TGFbetastimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch.